The complete responses in 2/3 patients are a strong early signal in a notoriously difficult-to-treat cancer. Monitor the conference call at 8:30am ET for additional patient details and timeline for FDA feedback on trial continuation. The stock could see significant upside if the data is viewed as de-risking the platform, but the small sample size (n=3) warrants caution, watch for any adverse safety signals or FDA delays.
DRTS drugs
DRTS drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 11 $10.34entry
- T+1 · 6mo ago −4.45%α −4.31% · $9.88
- T+5 · 6mo ago −3.00%α −2.91% · $10.03
- T+20 · 5mo ago −11.12%α −10.82% · $9.19
- T+60 · 3mo ago +28.24%α +23.85% · $13.26
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Alpha Tau reported groundbreaking interim data from its REGAIN trial for recurrent glioblastoma, showing complete responses in 2 of the first 3 patients with total disappearance of tumor lesions. The data is early (n=3) but highly promising in a devastating disease with few effective treatments, supporting the company's core strategy and potential FDA advancement.
Key Facts
- First 2 of 3 patients demonstrated complete response (total disappearance of all enhancing tumor lesions) per RANO criteria
- Third patient showed stable disease with 30% decrease in tumor dimension
- No local or distant recurrence in any patient as of May 3, 2026 cutoff
- One grade 3 SAE (seizure with temporary paralysis) observed, which resolved with steroids
- Trial expected to enroll up to 10 US patients with recurrent GBM not amenable to surgical resection
- FDA requested interim safety analysis; company awaiting FDA confirmation to continue enrollment
- Glioblastoma has ~14,000 new US cases/year, median survival ~8 months, 5-year survival <10%
Financial Impact
No financial figures disclosed; potential multi-billion dollar market opportunity if Alpha DaRT gains approval for GBM and other brain cancers
Risk Factors
- Very small sample size (n=3), early data may not replicate in larger cohort
- FDA may require additional safety data or halt enrollment
- Competing therapies (antiangiogenics, checkpoint inhibitors) could limit market adoption
- Company has limited operating history and needs additional funding for commercialization
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3291734 |
Track record
25 reports on DRTS
8 of 9 bullish or bearish reports moved the stock their way by T+60. Best: +68.80% at T+60 after the Apr 23, 2026 report. 11 of 12 went positive at some point.
Filters
- Nov 16, 2026today 6-K Bullish 6/10 Entry $14.50 Now $11.97 −17.45% settles Feb 12
- Nov 16, 2026today 6-K Bullish 6/10 Entry $15.46 Now $11.97 −22.56% settles Feb 12
- Nov 15, 20261d ago Press Release Bullish 7/10 Entry $13.35 Now $11.97 −10.34% settles Feb 12
- Nov 12, 20264d ago 6-K Neutral 3/10 Entry $13.36 Now $11.97 −10.40% settles Feb 10
- Oct 29, 202618d ago 6-K Neutral 3/10 Entry $13.23 Now $11.97 −9.52% settles Jan 27
- Oct 29, 202618d ago Press Release Neutral 3/10 Entry $13.23 Now $11.97 −9.52% settles Jan 27
- Oct 22, 202625d ago 6-K Neutral 4/10 Entry $12.90 Now $11.97 −7.21% settles Jan 20
- Oct 22, 202625d ago Press Release Neutral 3/10 Entry $12.90 Now $11.97 −7.21% settles Jan 20
- Oct 19, 202628d ago 6-K Bullish 6/10 Entry $12.62 Now $11.97 −5.15% settles Jan 14
- Oct 19, 202628d ago Press Release Bullish 7/10 Entry $12.62 Now $11.97 −5.15% settles Jan 14
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers